Congratulations to our 2023 graduates and award recipients. Commencement was held on June 9 at the InterContinental Mark Hopkins in San Francisco with an in-person and virtual ceremony. We were pleased to honor residents and fellows and their families for achieving this career milestone. Department faculty, alumni and senior department administrators attended the celebration, which included a number of award presentations for outstanding achievements in teaching, mentoring, clinical care, research and service.
Blog
The UC San Francisco Department of Radiology and Biomedical Imaging would like to thank our outstanding radiology residents for their dedication, focus and outstanding work over the past four years. We are proud of all that they have accomplished as residents and look forward to their contributions in the coming year.
On Wednesday, June 7, the UCSF Department of Radiology and Biomedical Imaging hosted a delegation of German political leaders and academics from the state of Schleswig-Holstein for the official launch of AI FLEX, a federated learning exchange project with great promise for advancing biomedical imaging and improving patient care.
There have been growing national efforts to diversify the radiology workforce, but are those efforts having an impact? Xiao Wu, MD, a resident at the UC San Francisco Department of Radiology and Biomedical Imaging, investigated the question and shared her findings in a journal article and a podcast.
Galateia Kazakia, PhD, and researchers in the Bone Quality Research Lab at UCSF are validating a ‘virtual bone biopsy’ using time-lapse High Resolution peripheral Quantitative Computed Tomography (HR-pQCT) for its potential to replace surgical bone biopsy.
Kondapa Naidu Bobba, PhD, is first author of "Evaluation of 134Ce/134La as a PET Imaging Theranostic Pair For 225Ac -Radiotherapeutics," a Journal of Nuclear Medicine (JNM) article published May 18 that discusses the development of a robust radiolabeling methodology and applied optimized method for utilizing prostate cancer targeting agents PSMA-617 and antibody YS5.